Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer. Curis's technology is principally based on targeting validated or novel targets for use in cancer treatment with a focus on the disruption of cancer networks. Curis maintains a Hedgehog pathway inhibitor program under collaboration with Genentech in which the lead molecule, GDC-0449, is currently in a pivotal Phase II clinical trial for advanced basal cell carcinoma as well in Phase II clinical testing for metastatic colorectal cancer and advanced ovarian cancer. In addition, Curis maintains proprietary cancer programs, which consist of a broad series of single and multi-targeted small molecule drug candidates. Each novel compound is rationally designed to inhibit one or more validated cancer targets, such as EGFR, Her2, Pi3k, Hsp90 and Bcr-Abl/Src. The multi-targeted inhibitors combine these targets with inhibition of histone deacetylase, or HDAC, into single small molecules for synergistic anti-tumor activity. The lead candidate from these programs is CUDC-101, which is an inhibitor of HDAC, EGFR and Her2 and is currently in Phase I clinical testing. Curis is also progressing single-targeted drug candidates, including Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor with unique pharmacological properties that may enable achievement of best-in-class status. We expect that our collaborator Debiopharm will begin a Phase I clinical trial for Debio 0932 in early 2010.